Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 10,564 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: Crohn Disease
Interventions: Ozanimod; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 190
States / cities: Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 142 more

Conditions: Deep Venous Thrombosis, Pulmonary Embolism
Interventions: Blood draw (Visit 1), Blood draw (Visits 2 and 3); Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 8 Years to 21 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 14
States / cities: Little Rock, Arkansas • St. Petersburg, Florida • Atlanta, Georgia + 11 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 80
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Conditions: Asthma
Interventions: Aerovant, placebo; Drug · Other
Lead sponsor: Aerovance, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 38
States / cities: Mobile, Alabama • Scottsdale, Arizona • Huntington Beach, California + 31 more

Conditions: Schizophrenia
Interventions: Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo, Paliperidone palmitate 100 mg eq.; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Anaheim, California • Cerritos, California • Escondido, California + 29 more

Conditions: Irritable Bowel Syndrome
Interventions: Not listed
Lead sponsor: Prometheus Laboratories; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 67
States / cities: Tuscaloosa, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 60 more

Conditions: Neck Pain
Interventions: Venlafaxine; Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Rochester, New York • Cincinnati, Ohio

Conditions: Neoplasm Malignant
Interventions: SAR302503 (TG101348), Placebo SAR302503, Panolosetron; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Los Angeles, California • Augusta, Georgia • Detroit, Michigan + 4 more

Conditions: HIV-1 Infection
Interventions: Aspirin, Placebo; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 10 more

Conditions: Infections, Rotavirus
Interventions: PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine, Lyophilized formulation of GSK's oral live attenuated HRV vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,351 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Birmingham, Alabama • Colorado Springs, Colorado • Louisville, Kentucky + 14 more

Conditions: Hepatitis C
Interventions: telaprevir, ribavirin, peginterferon alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more

Conditions: Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Acute Kidney Injury
Interventions: ANG-3777, Placebo; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 18 more

Conditions: Pulmonary Hypertension
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 18
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more

Conditions: Bipolar I Disorder, Bipolar II Disorder
Interventions: Icalcaprant, Placebo for Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 33
States / cities: Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 29 more

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and atorvastatin, Atorvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 78
States / cities: Birmingham, Alabama • Northport, Alabama • Sierra Vista, Arizona + 75 more

Conditions: Cholestasis
Interventions: sincalide; Drug
Lead sponsor: University of Michigan; Other
Eligibility: Up to 30 Days
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 6
States / cities: Baltimore, Maryland • Ann Arbor, Michigan • Rochester, New York + 3 more

Conditions: Elective Cranial Procedures With Dural Incision
Interventions: Adherus Dural Sealant; Device
Lead sponsor: HyperBranch Medical Technology, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Englewood, Colorado • Orlando, Florida • Tampa, Florida + 13 more

Conditions: Infant, Premature, Diseases, Bronchiolitis
Interventions: Oxygen saturation data visualization; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 12 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Duchenne Muscular Dystrophy
Interventions: IGF-1; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy, Volunteer
Interventions: Mirdametinib, Mirdametinib and Carbamazepine; Drug
Lead sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Infant Development
Interventions: Not listed
Lead sponsor: ByHeart; Industry
Eligibility: 0 Days to 5 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Birmingham, Alabama • Tuscan, Arizona • Jonesboro, Arkansas + 6 more

Conditions: Heart Failure
Interventions: hsTnT level; Other
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Indianapolis, Indiana • Detroit, Michigan • Cincinnati, Ohio + 1 more

Conditions: Hyperlipidemia
Interventions: Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo, Bococizumab 75mg placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Chandler, Arizona • Lincoln, California • Los Angeles, California + 25 more

Search by objective public record fields.

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Healing With Venlafaxine After Injury (HELP)

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

Modulation of Immune Activation by Aspirin

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis

Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures

Developing and Evaluating User-Designed Data Displays

Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy

To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants

Multi-Center Clinical Database of Infants for the Investigation of Early Nutrition Biomarkers

High Sensitivity cTnT Rules Out Cardiac Insufficiency Trial (TACIT)

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia